Based on the medical report provided, the patient has HER2-positive metastatic breast cancer with brain and liver involvement, and a germline pathogenic BRCA1 mutation. After reviewing the retrieved clinical trials, I have identified a few trials that may be relevant for this patient.

1. **NCT04646759**: Fulvestrant or Capecitabine Combined With Pyrotinib in HR-positive and HER2-Positive Metastatic Breast Cancer: A Multicenter, Randomized, Phase III Study

This trial is for patients with HR-positive and HER2-positive metastatic breast cancer, which aligns with the patient's condition. The trial is investigating the combination of fulvestrant or capecitabine with pyrotinib, a HER2 tyrosine kinase inhibitor. The patient's previous treatment with trastuzumab, ado-trastuzumab emtansine, and capecitabine/lapatinib suggests that they may benefit from a different treatment approach.

Expected prognosis outcome: The trial aims to evaluate the progression-free survival and incidence of grade 3 hand-foot syndrome in patients treated with fulvestrant or capecitabine combined with pyrotinib.

Possible risks: The trial's exclusion criteria include patients with central nervous system metastasis and clinical symptoms, which the patient has. However, the patient's brain metastases have been treated with gamma knife surgery, and they are currently asymptomatic.

Contact Information:
Ying Wang - CONTACT
Phone: 86-20-34070870, Email: wangy556@mail.sysu.edu.cn
Jianli Zhao - CONTACT
Phone: 86-20-34070499, Email: zhaojli5@mail.sysu.edu.cn

2. **NCT05950945**: A Phase 3b, Multicenter, Global, Interventional, Open-label Study of Trastuzumab Deruxtecan (T-DXd), an Anti-HER2-Antibody Drug Conjugate (ADC), in Subjects Who Have Unresectable and/or Metastatic HER2-low or HER2 Immunohistochemistry (IHC) 0 Breast Cancer (DESTINY-Breast15)

This trial is for patients with HER2-low or HER2 IHC 0 breast cancer, which is not the patient's exact condition. However, the trial is investigating trastuzumab deruxtecan, an anti-HER2 ADC, which may be beneficial for patients with HER2-positive breast cancer.

Expected prognosis outcome: The trial aims to evaluate the time from the start of T-DXd to initiation of subsequent anticancer treatment (TTNT).

Possible risks: The trial's exclusion criteria include patients with a history of severe hypersensitivity reactions to other monoclonal antibodies, which the patient may be at risk for given their previous treatment with trastuzumab and ado-trastuzumab emtansine.

Contact Information:
(US Sites) Daiichi Sankyo Contact for Clinical Trial Information - CONTACT
Phone: 908-992-6400, Email: CTRinfo@dsi.com
(Asia Sites) Daiichi Sankyo Contact for Clinical Trial Information - CONTACT
Phone: +81-3-6225-1111 (M-F 9-5 JST), Email: dsclinicaltrial@daiichisankyo.co.jp

3. **NCT05253911**: Tucatinib in Patients With Locally Advanced or Metastatic HER2-positive Breast Cancer Who Received at Least Two Prior Anti-HER2 Treatment Regimens: a Multicenter, International, Prospective, Non-interventional Study in Germany and Austria (TRACE)

This trial is for patients with locally advanced or metastatic HER2-positive breast cancer who have received at least two prior anti-HER2 treatment regimens. The trial is investigating the use of tucatinib, a HER2 tyrosine kinase inhibitor, in combination with trastuzumab and capecitabine.

Expected prognosis outcome: The trial aims to evaluate the time to deterioration of EORTC global health scale by at least 10 points.

Possible risks: The trial's exclusion criteria include patients with contraindications according to the SmPC of tucatinib, which the patient may be at risk for given their previous treatment with trastuzumab and ado-trastuzumab emtansine.

Contact Information:
Cathrin Hogrefe, Dr. - CONTACT
Phone: +49761152420, Email: Trace@iomedico.com

In conclusion, while these trials may be relevant for the patient, they also come with potential risks and uncertainties. It is essential to carefully review the inclusion and exclusion criteria, as well as the trial's objectives and potential benefits and risks, before making a decision.